Search results
Inhaled Insulin Could Help Folks With Type 1 Diabetes Avoid Needles
Fox Bangor· 17 hours agoInhaled insulin could be a better option than injections or pumps for some patients with type 1...
The 10 Best Performing Stocks So Far In 2024
Forbes· 3 days agoThe stocks have been on a tear with year-to-date gains ranging from 387% to more than a jaw-dropping 1,100% (as of June 14’s market close). The stock market has been buoyant in 2024, debunking ...
GenFleet Receives IND Approval from China's NMPA for GFH375, an Oral KRAS G12D (ON/OFF) Inhibitor,...
Tehachapi News· 6 days agoG12D mutation is the most prevalent KRAS mutation detected in human cancers, and no G12D-targeted therapies have been approved yet.
‘My husband had a stent fitted on holiday – but Co-op won’t pay his £10k hospital bill’
The Telegraph via Yahoo News· 3 days agoSince our return, my husband has been treated by the NHS for obstructive jaundice complicated by ...
Zentalis Pharmaceuticals’ (ZNTL) “Equal Weight” Rating Reaffirmed at Morgan Stanley
ETF DAILY NEWS· 6 days agoMorgan Stanley restated their equal weight rating on shares of Zentalis Pharmaceuticals (NASDAQ:ZNTL – Free Report) in a research note published on Tuesday morning, MarketBeat reports. Other ...
IgG4-Related Disease Affects Men More Often, More Severely
Medscape· 5 days agoA recent study highlighted sex-based differences in manifestations of IgG4-related disease.
Zentalis Pharmaceuticals (NASDAQ:ZNTL) Downgraded by UBS Group
ETF DAILY NEWS· 5 days agoZentalis Pharmaceuticals (NASDAQ:ZNTL – Get Free Report) was downgraded by UBS Group from a “buy” rating to a “neutral” rating in a report issued on Thursday, Briefing.com reports. UBS Group ...
Oppenheimer Lowers Zentalis Pharmaceuticals (NASDAQ:ZNTL) Price Target to $25.00
ETF DAILY NEWS· 6 days agoZentalis Pharmaceuticals (NASDAQ:ZNTL – Free Report) had its price objective trimmed by Oppenheimer from $50.00 to $25.00 in a report issued on Tuesday morning, Benzinga reports. Wells Fargo ...
Zentalis Pharmaceuticals (NASDAQ:ZNTL) Downgraded by Wedbush
ETF DAILY NEWS· 6 days agoWedbush downgraded shares of Zentalis Pharmaceuticals (NASDAQ:ZNTL – Free Report) from a neutral rating to an underperform rating in a research report sent to investors on Tuesday morning, MarketBeat ...
Zentalis Pharmaceuticals (NASDAQ:ZNTL) PT Lowered to $20.00 at HC Wainwright
ETF DAILY NEWS· 6 days agoZentalis Pharmaceuticals (NASDAQ:ZNTL – Free Report) had its price objective cut by HC Wainwright from $40.00 to $20.00 in a report issued on Tuesday morning, Benzinga reports. Stifel Nicolaus ...